Intensive care
Symposium
Cell therapy for ARDS and sepsis
Translational
Aims : After this session the attendees will understand the basic mechanisms and the roles of cell therapy in preclinical models of lung injury and severe sepsis and how to lead and implement first-in-human trials of lung cell therapy.
Target audience :
Anaesthesiologist, Immunologist, Intensivist/critical care physician, Microbiologist, Pulmonologist, Researcher, Resident, Scientist, Thoracic surgeon
08:30
Therapeutic efficacy of human mesenchymal cells (MSCs) in the repair of ARDS and VILI
J. Laffey(Galway, Ireland)
COI
-
Description
1
3286
09:00
Type II pneumocyte transplantation in ARDS
R. Guillamat Prats(Badalona, Spain)
COI
-
Description
2
3287
09:30
MSC therapy as adjuntive treatment in severe sepsis
M. Matthay(San Francisco, United States)
COI
-
Description
3
3288
10:00
What are the barriers to clinical translation of MSC for ARDS?
D. Mcauley(Belfast (Belfast), United Kingdom)
COI
-
Description
4
3289
. . .
